Healthcare >> CEO Interviews >> November 2, 2009
Dr. Joel E. Bernstein, M.D., is the Founder, Chief Executive Officer and a Director of Winston Pharmaceuticals. Before starting Winston, Dr. Bernstein was the Founder, Chairman and Chief Executive Officer of GenDerm Corporation, a pharmaceutical company that was acquired by Medicis Pharmaceutical Corporation in 1997. Previously Dr. Bernstein was head of dermatopharmacology at Northwestern University Medical School and the University of Chicago Pritzker School of Medicine. Dr. Bernstein has also held senior scientific positions at Abbott Laboratories and Schering-Plough Corporation. He has authored more than 125 scientific publications and holds over 150 patents. Dr. Bernstein received a B.A. from Carleton College and an M.D. from the University of Chicago Pritzker School of Medicine, where he received the Roche Award for ranking first in his class. He completed specialty-training programs in both dermatology and clinical pharmacology at the University of Chicago. Dr. Bernstein is a past President of the University of Chicago Medical and Biological Alumni Association. In 1988 he was chosen as Illinois high-tech entrepreneur of the year. Dr. Bernstein was also the Founder and Non-Executive Chairman of Sirius Laboratories, Inc., a dermatologic products company acquired by DUSA Pharmaceuticals in 2006. Profile
TWST: Tell us about Winston Pharmaceuticals.
Dr. Bernstein: Winston is a specialty pharma which is focused on developing new products for pain control. Right now the products that we have in
